Education
About Us
Working with TipRanks
Follow Us
Harvard Bioscience (HBIO)
:HBIO
HBIO Stock Chart & Stats
$0.40
-$0.02(-0.93%)
At close: 4:00 PM EST
$0.40
-$0.02(-0.93%)
Day’s Range― - ―
52-Week Range$0.28 - $2.38
Previous CloseN/A
Volume27.75K
Average Volume (3M)12.49M
Market Cap
$34.13M
Enterprise Value$55.51M
Total Cash (Recent Filing)$6.82M
Total Debt (Recent Filing)$42.78M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Mar 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding44,579,666
10 Day Avg. Volume1,186,947
30 Day Avg. Volume12,493,051
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.45
Price to Sales (P/S)0.98
P/FCF Ratio-76.30
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit1.14
Enterprise Value/Ebitda-1.27
Forecast
1Y Price Target
$2.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)$85.30M
Bulls Say, Bears Say
Bulls Say
Product DemandAn expanding backlog and demand for new products prompted a 4Q guide ahead of consensus.
Revenue GrowthHarvard Bioscience 3Q revenue beat consensus and gross margins improved year-over-year, boosted by across-the-board sales execution and financial discipline.
Sales PerformanceIn Europe (EMEA), sales increased sequentially and year-over-year, driven by higher pharma sales.
Bears Say
Government FundingA continuation of the government shutdown and a delay in the release of NIH funding would imply revenue at the lower end of the guidance range.
Market ConditionsIn China and Asia Pacific (APAC), products declined both sequentially and year-over-year due to tariff concerns.
Sector UncertaintyConcerns about basic research funding, drug pricing, and tariffs create an uncertain environment for the sector that seems likely to persist for the near future.
Harvard Bioscience News
HBIO FAQ
What was Harvard Bioscience’s price range in the past 12 months?
Harvard Bioscience lowest stock price was $0.28 and its highest was $2.38 in the past 12 months.
What is Harvard Bioscience’s market cap?
Harvard Bioscience’s market cap is $34.13M.
When is Harvard Bioscience’s upcoming earnings report date?
Harvard Bioscience’s upcoming earnings report date is Mar 05, 2026 which is in 92 days.
How were Harvard Bioscience’s earnings last quarter?
Harvard Bioscience released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.005 by -$0.005.
Is Harvard Bioscience overvalued?
According to Wall Street analysts Harvard Bioscience’s price is currently Undervalued.
Does Harvard Bioscience pay dividends?
Harvard Bioscience does not currently pay dividends.
What is Harvard Bioscience’s EPS estimate?
Harvard Bioscience’s EPS estimate is 0.04.
How many shares outstanding does Harvard Bioscience have?
Harvard Bioscience has 44,579,666 shares outstanding.
What happened to Harvard Bioscience’s price movement after its last earnings report?
Harvard Bioscience reported an EPS of $0 in its last earnings report, missing expectations of $0.005. Following the earnings report the stock price went down -7.313%.
Which hedge fund is a major shareholder of Harvard Bioscience?
Currently, no hedge funds are holding shares in HBIO
Harvard Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (400.00% Upside)
$2.00 (400.00% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 26.3%
Last 30 Days ▲ 26.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-65.40%
12-Months-Change
Fundamentals
Return on Equity
-135.62%
Trailing 12-Months
Asset Growth
-40.57%
Trailing 12-Months
Company Description
Harvard Bioscience
Harvard Bioscience (HBIO) is a global developer and manufacturer of a broad range of tools and instruments for life science research and drug development. The company operates in the biotechnology sector, focusing on providing innovative solutions for researchers in academic, pharmaceutical, and biotechnology environments. Its core products include advanced laboratory instruments, such as microinjection systems, electrophysiology equipment, and various assays and consumables that facilitate biological research and development.
HBIO Company Deck
HBIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong operational improvements, a significant increase in backlog and order growth, successful product launches, and positive cash flow management. However, these positives were somewhat offset by year-over-year revenue decline, challenges in the China market, and uncertainty due to the U.S. government shutdown affecting NIH funding. Overall, the company's efforts to enhance operational efficiency and increase product demand reflect a positive outlook despite some ongoing challenges.View all HBIO earnings summariesHBIO Stock 12 Month Forecast
Average Price Target
$2.00
▲(400.00% Upside)
Technical Analysis
Retractable Technologies
―
EKSO BIONICS
―
Milestone Scientific
―
NexGel Inc
―
Meihua International Medical Technologies Co., Ltd.
―
Ownership Overview
10.07% Insiders
8.81% Mutual Funds
20.72% Other Institutional Investors
56.57% Public Companies and
Individual Investors